189 related articles for article (PubMed ID: 37963224)
1. Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis.
Wang Y; Song Y; Qin C; Zhang C; Du Y; Xu T
Ann Med; 2023; 55(2):2281654. PubMed ID: 37963224
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
3. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
Lu L; Chen C; Cheng H; Ding H; Tian J; Wang H; Wang Z
BMC Cancer; 2023 Nov; 23(1):1066. PubMed ID: 37932689
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
[TBL] [Abstract][Full Text] [Related]
7. Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium.
Mir MC; Marchioni M; Zargar H; Zargar-Shoshtari K; Fairey AS; Mertens LS; Dinney CP; Krabbe LM; Cookson MS; Jacobsen NE; Griffin J; Montgomery JS; Vasdev N; Yu EY; Xylinas E; McGrath JS; Kassouf W; Dall'Era MA; Sridhar SS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Daneshmand D; Black PC
Eur Urol Focus; 2021 Nov; 7(6):1347-1354. PubMed ID: 32771446
[TBL] [Abstract][Full Text] [Related]
8. The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis.
Liu W; Tian J; Zhang S; Yang E; Shen H; Li F; Li K; Zhang T; Wang H; Svatek RS; Rodriguez R; Wang Z
Minerva Urol Nephrol; 2021 Apr; 73(2):144-153. PubMed ID: 31920065
[TBL] [Abstract][Full Text] [Related]
9. Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival.
Patel HD; Patel SH; Blanco-Martinez E; Kuzbel J; Chen VS; Druck A; Koehne EL; Patel PM; Doshi CP; Hahn NM; Hoffman-Censits JH; Berg S; Bivalacqua TJ; Kates M; Quek ML
J Urol; 2022 Jan; 207(1):77-85. PubMed ID: 34445890
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
Aydin AM; Cheriyan SK; Reich R; Hajiran A; Peyton CC; Zemp L; Yu A; Li R; Poch MA; Spiess PE; Jain R; Zhang J; Sexton WJ; Gilbert SM
Urol Oncol; 2022 Oct; 40(10):453.e19-453.e26. PubMed ID: 35811208
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer.
Sawasdee A; Tanthanuch M; Bejrananda T
Asian Pac J Cancer Prev; 2022 Nov; 23(11):3641-3647. PubMed ID: 36444575
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
13. Downstaging and Survival Associated with Neoadjuvant Immunotherapy Before Radical Cystectomy for Muscle-invasive Bladder Cancer.
Grassauer J; Schmidt J; Cowan A; Gilbert SM; Chakiryan NH
Eur Urol Oncol; 2024 Feb; 7(1):139-146. PubMed ID: 37453853
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience.
Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Tarrel R; Quevedo FJ; Cheville JC; Karnes RJ
World J Urol; 2019 Nov; 37(11):2409-2418. PubMed ID: 30805684
[TBL] [Abstract][Full Text] [Related]
16. Administration of neoadjuvant chemotherapy for muscle-invasive bladder cancer in real life: Are urologists still too cautious?
Such M; Lavolle A; Popelin MB; Thibault C; Fontaine E; Dariane C; Oudard S; Mejean A; Timsit MO; Audenet F
Prog Urol; 2021 May; 31(6):332-339. PubMed ID: 33468415
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111
[TBL] [Abstract][Full Text] [Related]
18. Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis.
Li G; Niu HM; Wu HT; Lei BY; Wang XH; Guo XB; Feng SL
Clin Invest Med; 2017 Apr; 40(2):E81-E94. PubMed ID: 28447581
[TBL] [Abstract][Full Text] [Related]
19. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study.
van Ginkel N; Hermans TJN; Meijer D; Boormans JL; Voortman J; Mertens L; van Beek SC; Vis AN;
Int Urol Nephrol; 2022 Dec; 54(12):3145-3152. PubMed ID: 35997906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
